BeOne Medicines (ONC) Research & Development (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Research & Development data on file, last reported at $541.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 12.31% year-over-year to $541.2 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 11.68% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 9.86% from the prior year.
• Research & Development for Q1 2026 stood at $541.2 million, down from $615.4 million in the prior quarter.
• Over the last five years, Research & Development for ONC reached as high as $615.4 million in Q4 2025 and fell as low as $378.2 million in Q2 2022.
• Historically, Research & Development has averaged $474.1 million across 5 years, with a median of $460.6 million in 2024.
• Across the five-year window, Research & Development surged 180.18% in 2022 and grew 4.61% in 2025, its largest moves.
• Year by year, Research & Development stood at $446.0 million in 2022, then grew by 10.75% to $494.0 million in 2023, then gained by 9.72% to $542.0 million in 2024, then rose by 13.54% to $615.4 million in 2025, then retreated by 12.06% to $541.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $541.2 million in Q1 2026, $615.4 million in Q4 2025, and $523.7 million in Q3 2025.